ClinicalTrials.gg

Program

Hepatitis B Virus Antisense Oligonucleotide AHB-137

Also written as “AHB-137”, “AHB-137 injection” and “AHB-137 (24 weeks)”.

Its studies are mostly in Hepatitis B, Chronic, led by 2 companies.

Furthest: phase 3, since Aug 12, 202511 company-led studies, 8 open or runningNext primary completion: Dec 12, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ausper Biopharma86 open or runningphase 3since Aug 12, 2025Oct 11, 2023Dec 12, 2026phase 2 · NCT07137910
AusperBio Therapeutics32 open or runningphase 2since Jan 19, 2026Jan 20, 2023May 11, 2027phase 2 · NCT07654283

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2023First study: phase 1 study in Hepatitis B, ChronicNew to AusperBio TherapeuticsAusperBio Therapeutics · NCT05717686 · 64 enrolled · United States, Hong Kong, New Zealand and more
  2. Oct 11, 2023Ausper Biopharma’s first study: phase 2 study in Hepatitis B, ChronicNew to Ausper BiopharmaAusper Biopharma · NCT06115993 · 129 enrolled · China
  3. Aug 5, 2024Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT06550128 · 86 enrolled · China
  4. May 16, 2025Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT06993480 · 20 enrolled · China
  5. Jun 25, 2025Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07069569 · 200 planned · China
  6. Aug 12, 2025Phase 3 study in Hepatitis B, ChronicAusper Biopharma · NCT07246889 · 577 enrolled · China
  7. Aug 15, 2025Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07137910 · 200 planned · China
  8. Jan 19, 2026Phase 2 study in Hepatitis B, ChronicPhase 2 reachedAusperBio Therapeutics · NCT07370207 · 84 planned · Australia, China, Japan and more
  9. May 14, 2026Phase 1 study in Hepatitis B, ChronicAusper Biopharma · NCT07600788 · 32 planned · China
  10. May 28, 2026Phase 2 study in Hepatitis B, ChronicAusperBio Therapeutics · NCT07654283 · 70 planned · United States, Canada, France and more
  11. May 28, 2026Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07635186 · 320 planned · China

Ahead

  1. Dec 12, 2026Primary completion: phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07137910
  2. Dec 18, 2026Primary completion: phase 3 study in Hepatitis B, ChronicAusper Biopharma · NCT07246889
  3. May 11, 2027Primary completion: phase 2 study in Hepatitis B, ChronicAusperBio Therapeutics · NCT07654283
  4. Jun 20, 2027Primary completion: phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07635186

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07654283Hepatitis B, Chronic · United States, Canada, France and more2RecruitingAusperBio TherapeuticsMay 11, 202770
NCT07635186Hepatitis B, Chronic · China2RecruitingAusper BiopharmaJun 20, 2027320
NCT07600788Hepatitis B, Chronic · China1RecruitingAusper BiopharmaMay 15, 202832
NCT07370207Hepatitis B, Chronic · Australia, China, Japan and more2RecruitingAusperBio TherapeuticsDec 31, 202884
NCT07137910Hepatitis B, Chronic · China2RecruitingAusper BiopharmaDec 12, 2026200
NCT07246889Hepatitis B, Chronic · China3Active, not recruitingAusper BiopharmaDec 18, 2026577
NCT07069569Hepatitis B, Chronic · China2RecruitingAusper BiopharmaJul 15, 2027200
NCT06993480Hepatitis B, Chronic · China2Active, not recruitingAusper BiopharmaJul 27, 202720
NCT06550128Hepatitis B, Chronic · China2CompletedAusper BiopharmaMay 26, 202586
NCT06115993Hepatitis B, Chronic · China2CompletedAusper BiopharmaDec 3, 2024129
NCT05717686Hepatitis B, Chronic · United States, Hong Kong, New Zealand and more1CompletedAusperBio TherapeuticsJan 7, 202564

How it is read

Names in the registry

  • “AHB-137”, 7 entries
  • “AHB-137 injection”, 3 entries
  • “AHB-137 (24 weeks)”, 1 entry
  • “AHB-137 (16 weeks)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Hepatitis B Virus Antisense Oligonucleotide AHB-137 (Ausper Biopharma): development program | ClinicalTrials.gg